RxDoctor Payments Data

Krishna Rao, MD

Hematology & Oncology · Springfield, ILNPI 1235128109

Payments from drug & device makers

$784,558in general payments, 2019–2025

Across 117 payments — averaging $6705.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$268K
  • Pfizer$138K
  • Eli Lilly$119K
  • F. Hoffmann-la Roche AG$92K
  • Genentech, Inc.$63K
  • Ascendis Pharma Endocrinology Inc$47K
  • plus $57K from 8 others
$2,918in research payments, 2019–2025

Across 9 payments — averaging $324.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K
  • AbbVie$848

What the payments were for

  • Consulting fees$50012%
  • Travel & lodging$2,63463%
  • Food & beverage$92822%
  • Education$1253%

General payments by program year

21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$784,558 in reported general payments places this provider in the 85th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$776,884
Medicare patients
294
Services billed
45,469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide23$506,768
LumakrasSotorasib11$118,458
Everolimus27$83,930
ZarxioFilgrastim-Sndz27$27,843
XareltoRivaroxaban14$11,034
EliquisApixaban11$8,036
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen48$1,170
Morphine Sulfate ErMorphine Sulfate26$835
Morphine Sulfate13$545
Gabapentin25$456
Tamoxifen Citrate25$401
Levothyroxine Sodium27$198
Mirtazapine13$166
Hydroxyurea16$118
Lidocaine-PrilocaineLidocaine/Prilocaine12$110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$93$11,03414 claims
PfizerEliquis$138,307$8,03611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →